Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict clot risk in rare blood cancers

NCT ID NCT07119970

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for better ways to predict blood clots in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will measure specific markers in the blood of 300 participants to see if they can tell who is at higher risk for clots. The goal is to improve prevention and treatment of these dangerous events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF) * JAK2V617F mutation with an allelic burden greater than 1% * High risk of thrombosis (age over 60 years or prior thrombotic event) * Diagnosis of MPN within the last 12 months * Enrollment in the AVAJAK clinical trial and the FIMBANK biobank * Affiliation with social security * Signed informed consent Exclusion Criteria: * Severe hepatic or renal insufficiency (Creatinine clearance \<30ml/min) * Patients under legal protection (guardianship or curatorship) * Patients under heparin treatment at inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera cellular phase chronic idiopathic myelofibrosis essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloproliferative disorders Myeloproliferative neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques

    NOT_YET_RECRUITING

    Paris, 75010, France

  • APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire

    NOT_YET_RECRUITING

    Le Kremlin-Bicêtre, 94270, France

  • APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire

    NOT_YET_RECRUITING

    Créteil, 94010, France

  • CH de Libourne, Service Hématologie

    RECRUITING

    Libourne, 33505, France

  • CH de Roubaix, Service Hématologie

    NOT_YET_RECRUITING

    Roubaix, 59100, France

  • CH de la Côte Basque, Service Hématologie

    NOT_YET_RECRUITING

    Bayonne, 64100, France

  • CH des Pays de Morlaix, Service Onco-Hématologie

    NOT_YET_RECRUITING

    Morlaix, 29672, France

  • CHD de Vendée, Service Onco-hématologie

    NOT_YET_RECRUITING

    La Roche-sur-Yon, 85925, France

  • CHU d'Angers, Service des maladies du Sang

    NOT_YET_RECRUITING

    Angers, 49933, France

  • CHU de Bordeaux, Service Hématologie Biologique

    NOT_YET_RECRUITING

    Bordeaux, 33600, France

  • CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire

    NOT_YET_RECRUITING

    Bordeaux, 33600, France

  • CHU de Brest, Service Hématologie et Hémostase Clinique

    NOT_YET_RECRUITING

    Brest, 29609, France

  • CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire

    NOT_YET_RECRUITING

    Limoges, 87042, France

  • CHU de Nantes, Service Hématologie Clinique

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • Hôpital Privé du Confluent, Service Hématologie

    NOT_YET_RECRUITING

    Nantes, 44202, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.